Skip to main content
Caplight Logo









Amber Bio

Amber Bio

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.amber.bio/

Last Round

Seed

Aug 3, 2023

Total Funding Raised

$26M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Amber Bio is a biotechnology company that provides genetic medicine solutions through a proprietary RNA-writing gene-editing platform designed to address diverse genetic mutations.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

RNA editinggene editingmulti-kilobase editinggenetic medicineCRISPR alternativeRNA therapeuticsgenomic medicinebiotech platformtherapeutic developmentRNA-based gene editinggenetic disease treatmentAI-augmented biotechnext-gen gene editingdrug discovery platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Amber Bio Comparables

Compare Amber Bio with similar companies based on industry and business-model similarity.

Amber Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shape Therapeutics
87%
Ascidian Therapeutics
85%
EDIRNA, Inc.
84%

Amber Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedAug 3, 2023

Key People

Founding team and executive leadership

Jacob Borrajo

Founder CEO

Founding Team

Amber Bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors increased 59% MoM.

  • Aug 3, 2023

    $26M round led by Andreessen Horowitz and Playground Global.

Amber Bio Filings

Explore SEC and related filing metadata, where available.

Amber Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Amber Bio's valuation, stock price, and market status.

Is Amber a public or private company?

Amber is a private company.

What is the current stock price of Amber?

Amber is a private company with no public stock price. No recent secondary market data is available.

How much is Amber worth (valuation)?

Valuation information for Amber is not publicly available.

Can I buy Amber stock?

Amber shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Amber's last funding round?

Amber's most recent funding round was Seed on August 3, 2023.

Who are the main investors in Amber?

Key investors in Amber include Andreessen Horowitz, Playground Global.

Will Amber IPO soon?

No public IPO plans have been announced for Amber.

How can I track Amber secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Amber's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range22
Year Founded2023
Last FundingAug 3, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?